AI Insight: AbbVie trades 32.2% above a high-confidence fair value estimate of $166.85, signaling potential overvaluation with valuation methods like DCF and P/E projecting substantially lower prices. High leverage (5/5) and low profitability (0/5) amplify financial risks, while wide Monte Carlo price dispersion and 83.3% downside risk indicate elevated volatility and uncertainty. Analyst targets and trading range valuations imply a more optimistic outlook, contrasting significant downside scenarios.